Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GENOMIC HEALTH INCGHDX · Entity 153816 | Chief Medical Officer | February 20, 2018 | February 22, 2018 |
| ILLUMINA, INC.ILMN · Entity 3137 | SVP Chief Medical Officer | March 01, 2023 | March 03, 2023 |
| VERACYTE, INC.VCYT · Entity 2018 | Chief Scientific & Med Officer | September 02, 2026 | September 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GENOMIC HEALTH INC
Report date February 20, 2018 · Filed February 22, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 21,387 |
Last balance in matching sequence
After 2018-02-20 transaction · row 2
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
2 source rowsRow 1 · 2018-02-20 · Sale · Disposed 4,642 · Balance 21,687 F1: These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on May 15, 2017. F2: Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated. F3: Represents weighted average sale price. Actual sale prices ranged from $32.34 to $33.32. F4: Includes an aggregate of 21,387 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. Row 2 · 2018-02-20 · Sale · Disposed 300 · Balance 21,387 F1: These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on May 15, 2017. F2: Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated. F5: Represents weighted average sale price. Actual sale prices ranged from $33.34 to $33.36. F4: Includes an aggregate of 21,387 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. |
Filing footnotes · ownership attribution and instrument terms
F1: These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on May 15, 2017.
F2: Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated.
F3: Represents weighted average sale price. Actual sale prices ranged from $32.34 to $33.32.
F4: Includes an aggregate of 21,387 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested.
F5: Represents weighted average sale price. Actual sale prices ranged from $33.34 to $33.36.
ILLUMINA, INC.
Report date March 01, 2023 · Filed March 03, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 14,786 |
Reported balance
After 2023-03-01 transaction · row 1
1 source rowRow 1 · 2023-03-01 · Grant · Acquired 7,556 · Balance 14,786 F1: Grant of restricted stock units shall vest as follows: 25% of the shares subject to the award shall vest on each of November 5, 2023, November 5, 2024, November 5, 2025, and November 5, 2026, subject to awardee's continuing status as a service provider on such dates. |
| Performance SharesSEC Table II · derivative / convertible security · Expires 2024-12-29 | Direct | 3,023 |
Reported balance
After 2023-03-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-03-01 · Grant · Acquired 3,023 · Balance 3,023 F2: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's earnings per share for the fiscal year ending December 29, 2024. The number of shares issued will range from 0% to 150% of the amount specified above, based on the company's actual earnings per share for the fiscal year ending December 29, 2024, relative to pre-defined objectives, subject to the awardee's continuing status as a service provider on such dates. |
| Performance SharesSEC Table II · derivative / convertible security · Expires 2025-12-28 | Direct | 4,534 |
Reported balance
After 2023-03-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-03-01 · Grant · Acquired 4,534 · Balance 4,534 F3: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's relative total shareholder return for the fiscal year ending December 28, 2025. The number of shares issued will range from 0% to 175% of the amount specified above, based on the company's relative total shareholder return for the fiscal year ending December 28, 2025, relative to pre-defined objectives, subject to the awardee's continuing status as a service provider on such dates. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of restricted stock units shall vest as follows: 25% of the shares subject to the award shall vest on each of November 5, 2023, November 5, 2024, November 5, 2025, and November 5, 2026, subject to awardee's continuing status as a service provider on such dates.
F2: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's earnings per share for the fiscal year ending December 29, 2024. The number of shares issued will range from 0% to 150% of the amount specified above, based on the company's actual earnings per share for the fiscal year ending December 29, 2024, relative to pre-defined objectives, subject to the awardee's continuing status as a service provider on such dates.
F3: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's relative total shareholder return for the fiscal year ending December 28, 2025. The number of shares issued will range from 0% to 175% of the amount specified above, based on the company's relative total shareholder return for the fiscal year ending December 28, 2025, relative to pre-defined objectives, subject to the awardee's continuing status as a service provider on such dates.
VERACYTE, INC.
Report date September 02, 2026 · Filed September 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 133,048 |
Ending reported balance
After 2026-09-04 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2026-09-02 · Tax withholding · Disposed 3,639 · Balance 146,158 F1: Represents shares of common stock withheld to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of certain restricted stock units on September 2, 2026 and does not represent a sale. Row 2 · 2026-09-04 · Sale · Disposed 10,405 · Balance 135,753 F2: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 21, 2025. F3: Represents weighted average sales price. Sale prices for the transactions range from $42.47 to $43.47. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Row 3 · 2026-09-04 · Sale · Disposed 2,705 · Balance 133,048 F2: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 21, 2025. F4: Represents weighted average sales price. Sale prices for the transactions range from $43.475 to $44.16. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock withheld to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of certain restricted stock units on September 2, 2026 and does not represent a sale.
F2: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 21, 2025.
F3: Represents weighted average sales price. Sale prices for the transactions range from $42.47 to $43.47. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.
F4: Represents weighted average sales price. Sale prices for the transactions range from $43.475 to $44.16. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
VARIAN MEDICAL SYSTEMS INC
Report date April 15, 2021 · Filed April 16, 2021
Section 16 reporting ended · disclosed 2021-04-16. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-04-15 transaction · row 1
1 source rowRow 1 · 2021-04-15 · Disposition to issuer · Disposed 1,699 · Balance 0 F1: Disposed of pursuant to merger agreement (the "Merger Agreement") between issuer and Siemens Healthineers I GmbH and certain other parties in exchange for a cash payment of $177.50 per share of common stock. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-04-15 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-04-15 · Disposition to issuer · Disposed 1,022 · Balance 0 F2: Each restricted stock unit represents a contingent right to receive one share of VAR common stock. F3: Pursuant to the Merger Agreement, these restricted stock units, which provided for vesting on the earlier of February 15, 2022, or the next Annual Meeting of Stockholders that occurs after the Grant Date, were cancelled in exchange for a cash payment of $177.50 per unvested share of underlying common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of pursuant to merger agreement (the "Merger Agreement") between issuer and Siemens Healthineers I GmbH and certain other parties in exchange for a cash payment of $177.50 per share of common stock.
F2: Each restricted stock unit represents a contingent right to receive one share of VAR common stock.
F3: Pursuant to the Merger Agreement, these restricted stock units, which provided for vesting on the earlier of February 15, 2022, or the next Annual Meeting of Stockholders that occurs after the Grant Date, were cancelled in exchange for a cash payment of $177.50 per unvested share of underlying common stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 04, 2026 Filed Sep 4, 2026 23:54 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 2,705 | $43.66 | $118,105.17 |
DisclosureSEC source: 0001649245-26-000009 · wk-form4_1788566051.xml · nonDerivative · entry 3 Febbo Phillip G. · CIK 0001649245 · Chief Scientific & Med Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 133,048 F2 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 21, 2025. F4 · price: Represents weighted average sales price. Sale prices for the transactions range from $43.475 to $44.16. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| September 04, 2026 Filed Sep 4, 2026 23:54 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 10,405 | $42.89 | $446,304.79 |
DisclosureSEC source: 0001649245-26-000009 · wk-form4_1788566051.xml · nonDerivative · entry 2 Febbo Phillip G. · CIK 0001649245 · Chief Scientific & Med Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 135,753 F2 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 21, 2025. F3 · price: Represents weighted average sales price. Sale prices for the transactions range from $42.47 to $43.47. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| September 02, 2026 Filed Sep 4, 2026 23:54 UTC | VERACYTE, INC. VCYT · Entity 2018 | Tax withholdingCommon Stock | 3,639 | $44.88 | $163,318.32 |
DisclosureSEC source: 0001649245-26-000009 · wk-form4_1788566051.xml · nonDerivative · entry 1 Febbo Phillip G. · CIK 0001649245 · Chief Scientific & Med Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 146,158 F1 · kind: Represents shares of common stock withheld to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of certain restricted stock units on September 2, 2026 and does not represent a sale. Read SEC document |
| June 02, 2026 Filed Jun 5, 2026 01:38 UTC | VERACYTE, INC. VCYT · Entity 2018 | Tax withholdingCommon Stock | 3,730 | $47.80 | $178,294.00 |
DisclosureSEC source: 0001649245-26-000007 · wk-form4_1780623512.xml · nonDerivative · entry 1 Febbo Phillip G. · CIK 0001649245 · Chief Scientific & Med Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 149,797 F1 · kind: Represents shares of common stock withheld to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of certain restricted stock units on June 2, 2026 and does not represent a sale. Read SEC document |
| March 06, 2026 Filed Mar 10, 2026 21:10 UTC | VERACYTE, INC. VCYT · Entity 2018 | GrantCommon Stock | 6,578 | $0.00 | $0.00 |
DisclosureSEC source: 0001649245-26-000006 · wk-form4_1773177016.xml · nonDerivative · entry 2 Febbo Phillip G. · CIK 0001649245 · Chief Scientific & Med Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 153,527 F2 · kind: Restricted stock units awarded on March 6, 2026 vest in full on the first anniversary of the date of grant subject to continuing employment of the Reporting Person on each vesting date. Read SEC document |
| March 06, 2026 Filed Mar 10, 2026 21:10 UTC | VERACYTE, INC. VCYT · Entity 2018 | GrantCommon Stock | 29,603 | $0.00 | $0.00 |
DisclosureSEC source: 0001649245-26-000006 · wk-form4_1773177016.xml · nonDerivative · entry 1 Febbo Phillip G. · CIK 0001649245 · Chief Scientific & Med Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 146,949 F1 · kind: Restricted stock units awarded on March 6, 2026 vest 25% on March 2, 2027 and 1/16 per quarter thereafter subject to continuing employment of the Reporting Person on each vesting date. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 21:16 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 13,425 | $36.16 | $485,429.21 |
DisclosureSEC source: 0001649245-26-000004 · wk-form4_1772659004.xml · nonDerivative · entry 2 Febbo Phillip G. · CIK 0001649245 · Chief Scientific & Med Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 117,346 F2 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 21, 2025. F3 · price: Represents weighted average sales price. Sale prices for the transactions range from $35.78 to $36.65. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 21:16 UTC | VERACYTE, INC. VCYT · Entity 2018 | Tax withholdingCommon Stock | 6,035 | $36.01 | $217,320.35 |
DisclosureSEC source: 0001649245-26-000004 · wk-form4_1772659004.xml · nonDerivative · entry 1 Febbo Phillip G. · CIK 0001649245 · Chief Scientific & Med Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 130,771 F1 · kind: Represents shares of common stock withheld to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of certain restricted stock units on March 2, 2026 and does not represent a sale. Read SEC document |
| February 26, 2026 Filed Mar 2, 2026 21:52 UTC | VERACYTE, INC. VCYT · Entity 2018 | Tax withholdingCommon Stock | 24,486 | $38.75 | $948,832.50 |
DisclosureSEC source: 0001649245-26-000002 · wk-form4_1772488374.xml · nonDerivative · entry 2 Febbo Phillip G. · CIK 0001649245 · Chief Scientific & Med Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 136,806 F2 · kind: Represents shares of common stock withheld to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of the PSUs and does not represent a sale. Read SEC document |
| February 26, 2026 Filed Mar 2, 2026 21:52 UTC | VERACYTE, INC. VCYT · Entity 2018 | GrantCommon Stock | 71,806 | $0.00 | $0.00 |
DisclosureSEC source: 0001649245-26-000002 · wk-form4_1772488374.xml · nonDerivative · entry 1 Febbo Phillip G. · CIK 0001649245 · Chief Scientific & Med Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 161,292 F1 · kind: Represents shares of common stock acquired by the Reporting Person upon vesting of certain performance based restricted stock units ("PSUs") on February 26, 2026, upon the certification by the Board of Directors of the Issuer of the achievement of the performance goals set forth therein. Of such PSUs, 47,863 PSUs vested on February 26, 2026, and the remaining 23,943 will vest on December 2, 2026, subject to the Reporting Person's continuous service to the Issuer through such date. Read SEC document |
| December 02, 2025 Filed Dec 5, 2025 00:44 UTC | VERACYTE, INC. VCYT · Entity 2018 | Tax withholdingCommon Stock | 2,955 | $46.16 | $136,402.80 |
DisclosureSEC source: 0001649245-25-000007 · wk-form4_1764895467.xml · nonDerivative · entry 1 Febbo Phillip G. · CIK 0001649245 · Chief Scientific & Med Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 89,486 F1 · kind: Represents shares of common stock withheld to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of certain restricted stock units on December 2, 2025 and does not represent a sale. Read SEC document |
| October 06, 2025 Filed Oct 7, 2025 20:27 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 8,349 | $36.02 | $300,709.27 |
DisclosureSEC source: 0001649245-25-000005 · wk-form4_1759868872.xml · nonDerivative · entry 1 Febbo Phillip G. · CIK 0001649245 · Chief Scientific & Med Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 92,441 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on September 4, 2024. F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $35.82 to $36.28. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 21:13 UTC | VERACYTE, INC. VCYT · Entity 2018 | Tax withholdingCommon Stock | 2,955 | $30.11 | $88,975.05 |
DisclosureSEC source: 0001384101-25-000116 · wk-form4_1757020419.xml · nonDerivative · entry 1 Febbo Phillip G. · CIK 0001649245 · Chief Scientific & Med Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,790 F1 · kind: Represents shares of common stock withheld to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of certain restricted stock units on September 2, 2025 and does not represent a sale. Read SEC document |
| June 02, 2025 Filed Jun 4, 2025 21:00 UTC | VERACYTE, INC. VCYT · Entity 2018 | Tax withholdingCommon Stock | 2,955 | $26.74 | $79,016.70 |
DisclosureSEC source: 0001384101-25-000068 · wk-form4_1749070838.xml · nonDerivative · entry 1 Febbo Phillip G. · CIK 0001649245 · Chief Scientific & Med Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 103,745 F1 · kind: The reporting person is reporting the withholding of 1,688 and 1,267 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 3,324 and 2,494 Restricted Stock Units, respectively, granted on October 2, 2023 and March 6, 2024, respectively, and does not represent a sale by the reporting person. Read SEC document |
| March 06, 2025 Filed Mar 10, 2025 20:44 UTC | VERACYTE, INC. VCYT · Entity 2018 | GrantCommon Stock | 24,160 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-25-000044 · wk-form4_1741639446.xml · nonDerivative · entry 1 Febbo Phillip G. · CIK 0001649245 · Chief Scientific & Med Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 106,700 F1 · kind: Restricted stock units awarded on March 6, 2025 vest 25% on March 2, 2026 and 1/16 per quarter thereafter subject to continuing employment of the Reporting Person on each vesting date. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 21:42 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 3,570 | $33.95 | $121,205.43 |
DisclosureSEC source: 0001384101-25-000032 · wk-form4_1741297319.xml · nonDerivative · entry 2 Febbo Phillip G. · CIK 0001649245 · Chief Scientific & Med Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 82,540 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on September 4, 2024. F3 · price: Represents weighted average sales price. Sale prices for the transactions range from $33.56 to $34.42. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| March 04, 2025 Filed Mar 6, 2025 21:42 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 4,467 | $32.86 | $146,807.51 |
DisclosureSEC source: 0001384101-25-000032 · wk-form4_1741297319.xml · nonDerivative · entry 1 Febbo Phillip G. · CIK 0001649245 · Chief Scientific & Med Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 86,110 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on September 4, 2024. F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $32.50 to $33.33. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| March 02, 2025 Filed Mar 3, 2025 21:30 UTC | VERACYTE, INC. VCYT · Entity 2018 | Tax withholdingCommon Stock | 6,754 | $34.76 | $234,769.04 |
DisclosureSEC source: 0001384101-25-000024 · wk-form4_1741037425.xml · nonDerivative · entry 3 Febbo Phillip G. · CIK 0001649245 · Chief Scientific & Med Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,577 F3 · kind: The reporting person is reporting the withholding of 1,688 and 5,066 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 3,323 and 9,976 Restricted Stock Units, respectively, granted on October 2, 2023 and March 6, 2024, respectively, and does not represent a sale by the reporting person. Read SEC document |
| February 27, 2025 Filed Mar 3, 2025 21:30 UTC | VERACYTE, INC. VCYT · Entity 2018 | Tax withholdingCommon Stock | 15,672 | $33.84 | $530,340.48 |
DisclosureSEC source: 0001384101-25-000024 · wk-form4_1741037425.xml · nonDerivative · entry 2 Febbo Phillip G. · CIK 0001649245 · Chief Scientific & Med Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,331 F2 · kind: Represents shares of common stock withheld to satisfy the Reporting Person's tax withholding obligations in connection with the vesting of the PSUs and does not represent a sale. Read SEC document |
| February 27, 2025 Filed Mar 3, 2025 21:30 UTC | VERACYTE, INC. VCYT · Entity 2018 | GrantCommon Stock | 30,589 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-25-000024 · wk-form4_1741037425.xml · nonDerivative · entry 1 Febbo Phillip G. · CIK 0001649245 · Chief Scientific & Med Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,003 F1 · kind: Represents shares of common stock acquired by the Reporting Person upon vesting of certain performance based restricted stock units ("PSUs") on February 27, 2025, upon the certification by the Board of Directors of the Issuer of the achievement of the performance goals set forth therein. Read SEC document |
| December 04, 2024 Filed Dec 6, 2024 21:34 UTC | VERACYTE, INC. VCYT · Entity 2018 | SaleCommon Stock | 3,934 | $44.09 | $173,447.31 |
DisclosureSEC source: 0001384101-24-000186 · wk-form4_1733520886.xml · nonDerivative · entry 1 Febbo Phillip G. · CIK 0001649245 · Chief Scientific & Med Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 82,414 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on September 4, 2024. F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $43.60 to $44.46. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 21:59 UTC | VERACYTE, INC. VCYT · Entity 2018 | Tax withholdingCommon Stock | 6,738 | $44.12 | $297,280.56 |
DisclosureSEC source: 0001384101-24-000179 · wk-form4_1733349551.xml · nonDerivative · entry 1 Febbo Phillip G. · CIK 0001649245 · Chief Scientific & Med Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 86,348 F1 · kind: The reporting person is reporting the withholding of 6,738 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 13,295 Restricted Stock Units granted on October 2, 2023 and does not represent a sale by the reporting person. Read SEC document |
| March 06, 2024 Filed Mar 8, 2024 21:36 UTC | VERACYTE, INC. VCYT · Entity 2018 | GrantCommon Stock | 39,904 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-24-000036 · wk-form4_1709933775.xml · nonDerivative · entry 1 Febbo Phillip G. · CIK 0001649245 · Chief Scientific & Med Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,086 F1 · kind: Restricted stock units awarded on March 6, 2024 vest 25% on March 2, 2025 and 1/16 per quarter thereafter subject to continuing employment of the Reporting Person on each vesting date. Read SEC document |
| October 02, 2023 Filed Oct 4, 2023 20:35 UTC | VERACYTE, INC. VCYT · Entity 2018 | GrantStock Option (right to buy) · Derivative | 85,858 | $0.00 Strike: $21.96 | $0.00 |
DisclosureSEC source: 0001384101-23-000155 · wk-form4_1696451687.xml · derivative · entry 2 Febbo Phillip G. · CIK 0001649245 · Chief Scientific & Med Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,858 Underlying: Common Stock · 85,858 shares Expires 2033-10-02 F2 · derivative.exercise_date: The option becomes exercisable as to 25% of the shares on October 2, 2024, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| October 02, 2023 Filed Oct 4, 2023 20:35 UTC | VERACYTE, INC. VCYT · Entity 2018 | GrantCommon Stock | 53,182 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-23-000155 · wk-form4_1696451687.xml · nonDerivative · entry 1 Febbo Phillip G. · CIK 0001649245 · Chief Scientific & Med Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,182 F1 · acquired: Restricted stock units awarded on October 2, 2023 vest 25% on December 2, 2024 and 1/16 per quarter thereafter subject to continuing employment of the Reporting Person on each vesting date. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 16:14 UTC | ILLUMINA, INC. ILMN · Entity 3137 | GrantPerformance Shares · Derivative | 4,534 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-008575 · form4.xml · derivative · entry 3 Febbo Phillip G. · CIK 0001649245 · SVP Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,534 Underlying: Common Stock · 4,534 shares Expires 2025-12-28 F3 · derivative.exercise_price: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's relative total shareholder return for the fiscal year ending December 28, 2025. The number of shares issued will range from 0% to 175% of the amount specified above, based on the company's relative total shareholder return for the fiscal year ending December 28, 2025, relative to pre-defined objectives, subject to the awardee's continuing status as a service provider on such dates. F3 · derivative.exercise_date: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's relative total shareholder return for the fiscal year ending December 28, 2025. The number of shares issued will range from 0% to 175% of the amount specified above, based on the company's relative total shareholder return for the fiscal year ending December 28, 2025, relative to pre-defined objectives, subject to the awardee's continuing status as a service provider on such dates. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 16:14 UTC | ILLUMINA, INC. ILMN · Entity 3137 | GrantPerformance Shares · Derivative | 3,023 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-008575 · form4.xml · derivative · entry 2 Febbo Phillip G. · CIK 0001649245 · SVP Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,023 Underlying: Common Stock · 3,023 shares Expires 2024-12-29 F2 · derivative.exercise_price: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's earnings per share for the fiscal year ending December 29, 2024. The number of shares issued will range from 0% to 150% of the amount specified above, based on the company's actual earnings per share for the fiscal year ending December 29, 2024, relative to pre-defined objectives, subject to the awardee's continuing status as a service provider on such dates. F2 · derivative.exercise_date: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's earnings per share for the fiscal year ending December 29, 2024. The number of shares issued will range from 0% to 150% of the amount specified above, based on the company's actual earnings per share for the fiscal year ending December 29, 2024, relative to pre-defined objectives, subject to the awardee's continuing status as a service provider on such dates. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 16:14 UTC | ILLUMINA, INC. ILMN · Entity 3137 | GrantCommon Stock | 7,556 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-008575 · form4.xml · nonDerivative · entry 1 Febbo Phillip G. · CIK 0001649245 · SVP Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,786 F1 · shares: Grant of restricted stock units shall vest as follows: 25% of the shares subject to the award shall vest on each of November 5, 2023, November 5, 2024, November 5, 2025, and November 5, 2026, subject to awardee's continuing status as a service provider on such dates. Read SEC document |
| February 21, 2023 Filed Feb 23, 2023 22:34 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Exercise / conversionPerformance Shares · Derivative | 3,522 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-006823 · form4.xml · derivative · entry 3 Febbo Phillip G. · CIK 0001649245 · SVP Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,522 shares Expires 2023-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares of stock awarded as a result of the Company achieving at least 94% of the applicable performance criteria pursuant to the reporting person's grant of performance share units on February 5, 2020. F1 · shares: Represents shares of stock awarded as a result of the Company achieving at least 94% of the applicable performance criteria pursuant to the reporting person's grant of performance share units on February 5, 2020. F1 · derivative.exercise_date: Represents shares of stock awarded as a result of the Company achieving at least 94% of the applicable performance criteria pursuant to the reporting person's grant of performance share units on February 5, 2020. Read SEC document |
| February 21, 2023 Filed Feb 23, 2023 22:34 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Tax withholdingCommon Stock | 1,245 | $202.84 | $252,535.80 |
DisclosureSEC source: 0001127602-23-006823 · form4.xml · nonDerivative · entry 2 Febbo Phillip G. · CIK 0001649245 · SVP Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,230 Read SEC document |
| February 21, 2023 Filed Feb 23, 2023 22:34 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Exercise / conversionCommon Stock | 3,522 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-006823 · form4.xml · nonDerivative · entry 1 Febbo Phillip G. · CIK 0001649245 · SVP Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,475 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of stock awarded as a result of the Company achieving at least 94% of the applicable performance criteria pursuant to the reporting person's grant of performance share units on February 5, 2020. Read SEC document |
| November 05, 2022 Filed Nov 8, 2022 22:01 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Tax withholdingCommon Stock | 821 | $217.19 | $178,312.99 |
DisclosureSEC source: 0001127602-22-025123 · form4.xml · nonDerivative · entry 1 Febbo Phillip G. · CIK 0001649245 · SVP Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,953 Read SEC document |
| April 06, 2022 Filed Apr 7, 2022 20:19 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 1,988 | $360.01 | $715,699.88 |
DisclosureSEC source: 0001127602-22-011725 · form4.xml · nonDerivative · entry 2 Febbo Phillip G. · CIK 0001649245 · SVP Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,774 F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document |
| April 05, 2022 Filed Apr 7, 2022 20:19 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Tax withholdingCommon Stock | 131 | $363.84 | $47,663.04 |
DisclosureSEC source: 0001127602-22-011725 · form4.xml · nonDerivative · entry 1 Febbo Phillip G. · CIK 0001649245 · SVP Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,762 Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 23:28 UTC | ILLUMINA, INC. ILMN · Entity 3137 | GrantPerformance Shares · Derivative | 9,085 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-008112 · form4.xml · derivative · entry 2 Febbo Phillip G. · CIK 0001649245 · SVP Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,085 Underlying: Common Stock · 9,085 shares Expires 2024-12-29 F2 · derivative.exercise_price: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's earnings per share for the fiscal year ending December 29, 2024. The number of shares issued will range from 0% to 200% of the amount specified above, based on the company's actual earnings per share for the fiscal year ending December 29, 2024, relative to pre-defined objectives, subject to the awardee's continuing status as a service provider on such dates. F2 · derivative.exercise_date: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's earnings per share for the fiscal year ending December 29, 2024. The number of shares issued will range from 0% to 200% of the amount specified above, based on the company's actual earnings per share for the fiscal year ending December 29, 2024, relative to pre-defined objectives, subject to the awardee's continuing status as a service provider on such dates. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 23:28 UTC | ILLUMINA, INC. ILMN · Entity 3137 | GrantCommon Stock | 3,029 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-008112 · form4.xml · nonDerivative · entry 1 Febbo Phillip G. · CIK 0001649245 · SVP Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,893 F1 · shares: Grant of restricted stock units shall vest as follows: 25% of the shares subject to the award shall vest on each of November 5, 2022, November 5, 2023, November 5, 2024, and November 5, 2025, subject to the awardee's continuing status as a service provider on such dates. Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 22:32 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Exercise / conversionPerformance Shares · Derivative | 2,851 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-006616 · form4.xml · derivative · entry 3 Febbo Phillip G. · CIK 0001649245 · SVP Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,851 shares Expires 2022-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares of stock awarded as a result of the Company achieving at least 100% of the applicable performance criteria pursuant to the reporting person's grant of performance share units on December 11, 2018. F1 · shares: Represents shares of stock awarded as a result of the Company achieving at least 100% of the applicable performance criteria pursuant to the reporting person's grant of performance share units on December 11, 2018. F1 · derivative.exercise_date: Represents shares of stock awarded as a result of the Company achieving at least 100% of the applicable performance criteria pursuant to the reporting person's grant of performance share units on December 11, 2018. Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 22:32 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Tax withholdingCommon Stock | 1,002 | $319.86 | $320,499.72 |
DisclosureSEC source: 0001127602-22-006616 · form4.xml · nonDerivative · entry 2 Febbo Phillip G. · CIK 0001649245 · SVP Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,864 Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 22:32 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Exercise / conversionCommon Stock | 2,851 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-006616 · form4.xml · nonDerivative · entry 1 Febbo Phillip G. · CIK 0001649245 · SVP Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,866 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of stock awarded as a result of the Company achieving at least 100% of the applicable performance criteria pursuant to the reporting person's grant of performance share units on December 11, 2018. Read SEC document |
| November 08, 2021 Filed Nov 9, 2021 21:59 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 1,000 | $406.83 | $406,830.00 |
DisclosureSEC source: 0001127602-21-028723 · form4.xml · nonDerivative · entry 2 Febbo Phillip G. · CIK 0001649245 · SVP Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,015 F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document |
| November 05, 2021 Filed Nov 9, 2021 21:59 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Tax withholdingCommon Stock | 446 | $408.14 | $182,030.44 |
DisclosureSEC source: 0001127602-21-028723 · form4.xml · nonDerivative · entry 1 Febbo Phillip G. · CIK 0001649245 · SVP Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,015 Read SEC document |
| June 11, 2021 Filed Jun 14, 2021 21:50 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 290 | $449.02 | $130,215.80 |
DisclosureSEC source: 0001127602-21-019827 · form4.xml · nonDerivative · entry 3 Febbo Phillip G. · CIK 0001649245 · SVP Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,461 F1 · shares: The sale was made pursuant to a 10b5-1 plan. Read SEC document |
| June 11, 2021 Filed Jun 14, 2021 21:50 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 400 | $447.65 | $179,060.00 |
DisclosureSEC source: 0001127602-21-019827 · form4.xml · nonDerivative · entry 2 Febbo Phillip G. · CIK 0001649245 · SVP Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,751 F1 · shares: The sale was made pursuant to a 10b5-1 plan. F3 · price: Weighted average sale price representing 400 shares sold ranging from $447.28 to $448.02 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. Read SEC document |
| June 11, 2021 Filed Jun 14, 2021 21:50 UTC | ILLUMINA, INC. ILMN · Entity 3137 | SaleCommon Stock | 310 | $446.17 | $138,312.70 |
DisclosureSEC source: 0001127602-21-019827 · form4.xml · nonDerivative · entry 1 Febbo Phillip G. · CIK 0001649245 · SVP Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,151 F1 · shares: The sale was made pursuant to a 10b5-1 plan. F2 · price: Weighted average sale price representing 310 shares sold ranging from $446.14 to $446.24 per share. Number of shares sold at each separate price will be made available to the SEC staff, the issuer, or a security holder of the issuer upon request. Read SEC document |
| April 15, 2021 Filed Apr 16, 2021 19:56 UTC | VARIAN MEDICAL SYSTEMS INC VAR · Entity 140252 | Disposition to issuerRestricted Stock Units · Derivative | 1,022 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-013920 · form4.xml · derivative · entry 2 Febbo Phillip G. · CIK 0001649245 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,022 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of VAR common stock. F3 · price: Pursuant to the Merger Agreement, these restricted stock units, which provided for vesting on the earlier of February 15, 2022, or the next Annual Meeting of Stockholders that occurs after the Grant Date, were cancelled in exchange for a cash payment of $177.50 per unvested share of underlying common stock. F3 · derivative.exercise_date: Pursuant to the Merger Agreement, these restricted stock units, which provided for vesting on the earlier of February 15, 2022, or the next Annual Meeting of Stockholders that occurs after the Grant Date, were cancelled in exchange for a cash payment of $177.50 per unvested share of underlying common stock. F3 · derivative.expiration_date: Pursuant to the Merger Agreement, these restricted stock units, which provided for vesting on the earlier of February 15, 2022, or the next Annual Meeting of Stockholders that occurs after the Grant Date, were cancelled in exchange for a cash payment of $177.50 per unvested share of underlying common stock. Read SEC document |
| April 15, 2021 Filed Apr 16, 2021 19:56 UTC | VARIAN MEDICAL SYSTEMS INC VAR · Entity 140252 | Disposition to issuerCommon Stock | 1,699 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-21-013920 · form4.xml · nonDerivative · entry 1 Febbo Phillip G. · CIK 0001649245 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Disposed of pursuant to merger agreement (the "Merger Agreement") between issuer and Siemens Healthineers I GmbH and certain other parties in exchange for a cash payment of $177.50 per share of common stock. Read SEC document |
| April 05, 2021 Filed Apr 7, 2021 20:38 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Tax withholdingCommon Stock | 131 | $384.54 | $50,374.74 |
DisclosureSEC source: 0001127602-21-013414 · form4.xml · nonDerivative · entry 1 Febbo Phillip G. · CIK 0001649245 · SVP Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,461 Read SEC document |
| February 17, 2021 Filed Feb 18, 2021 21:44 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Exercise / conversionPerformance Shares · Derivative | 3,173 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006514 · form4.xml · derivative · entry 4 Febbo Phillip G. · CIK 0001649245 · SVP Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,173 shares Expires 2021-01-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Represents shares of stock awarded as a result of the Company achieving at least 100% of the applicable performance criteria pursuant to the reporting person's grant of performance share units on December 11, 2017. F2 · shares: Represents shares of stock awarded as a result of the Company achieving at least 100% of the applicable performance criteria pursuant to the reporting person's grant of performance share units on December 11, 2017. F2 · derivative.exercise_date: Represents shares of stock awarded as a result of the Company achieving at least 100% of the applicable performance criteria pursuant to the reporting person's grant of performance share units on December 11, 2017. Read SEC document |
| February 17, 2021 Filed Feb 18, 2021 21:44 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Tax withholdingCommon Stock | 1,454 | $494.24 | $718,624.96 |
DisclosureSEC source: 0001127602-21-006514 · form4.xml · nonDerivative · entry 3 Febbo Phillip G. · CIK 0001649245 · SVP Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,592 Read SEC document |
| February 17, 2021 Filed Feb 18, 2021 21:44 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Exercise / conversionCommon Stock | 3,173 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-006514 · form4.xml · nonDerivative · entry 2 Febbo Phillip G. · CIK 0001649245 · SVP Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,046 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: Represents shares of stock awarded as a result of the Company achieving at least 100% of the applicable performance criteria pursuant to the reporting person's grant of performance share units on December 11, 2017. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.